Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1993 1
1996 1
2002 2
2003 3
2004 1
2006 1
2008 2
2009 1
2011 1
2012 2
2016 3
2017 2
2018 1
2019 4
2020 1
2021 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Update of EULAR recommendations for the treatment of systemic sclerosis.
Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors. Kowal-Bielecka O, et al. Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9. Ann Rheum Dis. 2017. PMID: 27941129 Free article.
All centres from the EULAR Scleroderma Trials and Research group were invited to submit and select clinical questions concerning SSc treatment using a Delphi approach. ...The procedure resulted in 16 recommendations being developed (instead of 14 in 2009) that address trea …
All centres from the EULAR Scleroderma Trials and Research group were invited to submit and select clinical questions concerning SSc …
Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
Zhao M, Wu J, Wu H, Sawalha AH, Lu Q. Zhao M, et al. Clin Rev Allergy Immunol. 2022 Apr;62(2):273-291. doi: 10.1007/s12016-020-08831-4. Epub 2021 Jan 15. Clin Rev Allergy Immunol. 2022. PMID: 33449302 Review.
Fatal outcomes in SSc often originate from organ complications of the disease, such as lung fibrosis, pulmonary artery hypertension (PAH), and scleroderma renal crisis (SRC). Current treatment modalities in SSc have focused on targeting vascular damage, fibro …
Fatal outcomes in SSc often originate from organ complications of the disease, such as lung fibrosis, pulmonary artery hypertension (PAH), a …
Treatment Algorithms for Systemic Sclerosis According to Experts.
Fernández-Codina A, Walker KM, Pope JE; Scleroderma Algorithm Group. Fernández-Codina A, et al. Arthritis Rheumatol. 2018 Nov;70(11):1820-1828. doi: 10.1002/art.40560. Epub 2018 Sep 17. Arthritis Rheumatol. 2018. PMID: 29781586
We undertook this study to generate SSc treatment algorithms endorsed by a high percentage of SSc experts. METHODS: Experts from the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research group (n = 170) were asked whether they agreed with SSc …
We undertook this study to generate SSc treatment algorithms endorsed by a high percentage of SSc experts. METHODS: Experts from the Scle …
Management of scleroderma renal crisis.
Nagaraja V. Nagaraja V. Curr Opin Rheumatol. 2019 May;31(3):223-230. doi: 10.1097/BOR.0000000000000604. Curr Opin Rheumatol. 2019. PMID: 30870219 Review.
PURPOSE OF REVIEW: Scleroderma renal crisis (SRC) is a life-threatening manifestation in systemic sclerosis (SSc) and is usually presented by an acute onset of severe hypertension together with an acute kidney injury. ...SUMMARY: Early diagnosis of SRC is the …
PURPOSE OF REVIEW: Scleroderma renal crisis (SRC) is a life-threatening manifestation in systemic sclerosis (SSc) and i …
Towards developing criteria for scleroderma renal crisis: A scoping review.
Hoa S, Stern EP, Denton CP, Hudson M; Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group Investigators of the Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group. Hoa S, et al. Autoimmun Rev. 2017 Apr;16(4):407-415. doi: 10.1016/j.autrev.2017.02.012. Epub 2017 Feb 14. Autoimmun Rev. 2017. PMID: 28212921 Free article. Review.
OBJECTIVE: The absence of a gold standard for scleroderma renal crisis (SRC) has hindered our understanding of this problem. ...Papers were eligible for inclusion if they were full-length articles in English whose main topic was SRC or scleroderma r …
OBJECTIVE: The absence of a gold standard for scleroderma renal crisis (SRC) has hindered our understanding of this pro …
Management review of scleroderma renal crisis: An update with practical pointers.
Foocharoen C, Tonsawan P, Pongkulkiat P, Anutrakulchai S, Mahakkanukrauh A, Suwannaroj S. Foocharoen C, et al. Mod Rheumatol. 2023 Jan 3;33(1):12-20. doi: 10.1093/mr/roac028. Mod Rheumatol. 2023. PMID: 35349704
Scleroderma renal crisis (SRC) represents severe, fatal internal organ involvement brought on by systemic sclerosis. A high rate of renal replacement therapy and mortality persists despite various treatments. ...
Scleroderma renal crisis (SRC) represents severe, fatal internal organ involvement brought on by systemic sclerosis. A …
Treatment of systemic sclerosis.
Pope JE. Pope JE. Rheum Dis Clin North Am. 1996 Nov;22(4):893-907. doi: 10.1016/s0889-857x(05)70307-0. Rheum Dis Clin North Am. 1996. PMID: 8923602 Review.
Raynaud's phenomenon can be treated with calcium channel blockers and iloprost. Scleroderma renal crisis can be treated with aggressive blood pressure control using angiotensin converting enzyme inhibitors. The best treatment for rapidly progressive sclero …
Raynaud's phenomenon can be treated with calcium channel blockers and iloprost. Scleroderma renal crisis can be treated …
Diagnosis, management and prevention of scleroderma renal disease.
Penn H, Denton CP. Penn H, et al. Curr Opin Rheumatol. 2008 Nov;20(6):692-6. doi: 10.1097/BOR.0b013e3283108df7. Curr Opin Rheumatol. 2008. PMID: 18946330 Review.
PURPOSE OF REVIEW: Renal complications are important in scleroderma (systemic sclerosis) and include scleroderma renal crisis. ...SUMMARY: Renal involvement remains a major complication of scleroderma. Long-term outcome after re …
PURPOSE OF REVIEW: Renal complications are important in scleroderma (systemic sclerosis) and include scleroderma ren …
Evaluation and management of alveolitis and interstitial lung disease in scleroderma.
Latsi PI, Wells AU. Latsi PI, et al. Curr Opin Rheumatol. 2003 Nov;15(6):748-55. doi: 10.1097/00002281-200311000-00011. Curr Opin Rheumatol. 2003. PMID: 14569205 Review.
Best current initial treatment consists of either oral or intravenous cyclophosphamide, usually administered with low-dose corticosteroid therapy, although the risk of scleroderma renal crisis with low-dose steroid therapy requires further evalu …
Best current initial treatment consists of either oral or intravenous cyclophosphamide, usually administered with low-dose corticosteroid …
Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management.
Shanmugam VK, Steen VD. Shanmugam VK, et al. Curr Opin Rheumatol. 2012 Nov;24(6):669-76. doi: 10.1097/BOR.0b013e3283588dcf. Curr Opin Rheumatol. 2012. PMID: 22955019 Free PMC article. Review.
PURPOSE OF REVIEW: Renal disease remains an important cause of morbidity and mortality in scleroderma. The spectrum of renal complications in systemic sclerosis includes scleroderma renal crisis (SRC), normotensive renal crisis …
PURPOSE OF REVIEW: Renal disease remains an important cause of morbidity and mortality in scleroderma. The spectrum of rena …
29 results